Zoetis Inc. — 2021 Form 10-K Summary
Business context and reporting period
Zoetis is a global animal-health company developing and selling medicines, vaccines, diagnostics and related products for companion animals and livestock. This annual report covers the fiscal year ended December 31, 2021; it does not provide separate fourth-quarter results. The company reports U.S. and International operating segments. Companion animals accounted for about 60% of revenue, livestock about 39%, and contract manufacturing and human-health products about 1%.
Financial performance and liquidity
- Revenue was $7.776 billion, up 16% from 2020; operational growth was 15%, with foreign exchange contributing about 1 percentage point. Growth reflected in-line product volume (+9%), new-product volume (+5%) and price (+1%).
- Net income attributable to Zoetis was $2.037 billion, up 24%; diluted EPS was $4.27, up 25%. Adjusted net income, a non-GAAP measure, was $2.240 billion, up 21%; adjusted diluted EPS was $4.70, up 22%.
- Income before tax was $2.488 billion (32% of revenue); the effective tax rate was 18.2%, compared with 18.0% in 2020. Cost of sales was 30% of revenue, versus 31% a year earlier. SG&A was 26% of revenue and R&D was 7%.
- U.S. revenue rose 14% to $4.042 billion; International revenue rose 20% to $3.652 billion. Segment earnings were $2.569 billion for the U.S. (+15%) and $1.948 billion for International (+26%). U.S. companion-animal revenue grew 25%, while U.S. livestock revenue declined 10%.
- Operating cash flow was $2.213 billion, up from $2.126 billion. Capital expenditures were $477 million; cash used in investing activities was $458 million and cash used in financing activities was $1.862 billion. Cash and equivalents ended the year at $3.485 billion.
- Working capital was $5.133 billion and the current ratio was 3.86:1. Long-term debt, net of discount and issuance costs, was $6.592 billion; gross principal debt was $6.650 billion. The company had no revolver or commercial-paper borrowings outstanding and reported compliance with its credit-facility covenants.
- Dividends declared were $1.075 per share, versus $0.850 in 2020. Zoetis repurchased approximately 4.0 million shares during 2021 and authorized a new $3.5 billion repurchase program in December.
Material changes versus 2020
- Companion-animal revenue increased 28% to $4.689 billion, led by parasiticides and dermatology products. Livestock revenue increased 2% to $3.005 billion overall, but U.S. livestock sales fell amid generic competition, cost pressures, smaller poultry flocks and pricing pressure.
- International growth included companion-animal products and livestock gains in cattle, swine and fish. Foreign exchange added about $98 million to International revenue.
- Net income growth outpaced revenue growth, while the effective tax rate edged higher. SG&A increased 16% and R&D increased 10%, reflecting investment, compensation, logistics and currency effects.
- Operating cash flow rose modestly, while financing cash flow shifted from a $123 million source in 2020 to a $1.862 billion use in 2021, primarily due to debt repayments, share repurchases and dividends.
Outlook, commentary, risks and unusual items
- The supplied filing text refers to 2022 financial guidance but does not provide its numerical targets. Management expected COVID-19-related effects to continue into 2022 and anticipated some supply challenges to persist.
- In 2021, isolated supply constraints affected Librela, Solensia and other products, driven by strong demand and competition for manufacturing inputs. Management described supply optimizations, controlled launches and customer coordination as mitigation measures.
- Key risks include dependence on successful top-selling products (the top five contributed about 33% of revenue), generic competition, product safety or quality issues, supply interruptions, customer/distributor consolidation, restrictions on livestock antibacterials, foreign-exchange movements, inflation, regulation, cyber and data-privacy risks, and animal disease, weather and climate impacts.
- Draxxin sales declined 12% in the U.S. in its first year of generic competition; further declines were expected. The filing also identifies upcoming or existing generic exposure for other products, including ceftiofur, Convenia and Cerenia.
- Unusual items included $73 million of pre-tax “certain significant items,” primarily asset impairments and restructuring/productivity costs; adjusted net income excludes these and other specified items. Impairments affected assets in dairy cattle, diagnostics, aquatic health and manufacturing.
- Zoetis disclosed a voluntary OFAC and Department of Justice disclosure concerning potentially prohibited Iran-related transactions by acquired business Platinum Performance. It also described ongoing legal and environmental matters; management said it could not estimate the reasonably possible loss beyond recorded accruals for substantially all legal contingencies.
- The planned acquisition of Australian animal-health company Jurox was subject to customary closing conditions, with completion expected in 2022. Auditors issued unqualified opinions on the financial statements and internal controls; two critical audit matters concerned uncertain tax benefits and U.S. rebate accruals.
Most important facts for investors to verify
- Review the company’s 2022 guidance and subsequent updates, since numerical guidance is not included in the supplied filing text.
- Track growth, margins and supply capacity for leading companion-animal products, especially Apoquel, Simparica/Simparica Trio, Librela and Solensia.
- Assess the pace and commercial impact of generic competition, particularly for Draxxin and ceftiofur products.
- Monitor U.S. livestock performance, including input-cost pressures, poultry and swine demand, and antibacterial-use restrictions.
- Check debt maturities, refinancing plans, interest-rate exposure and capital returns against cash generation and liquidity.
- Follow the resolution and financial consequences, if any, of the Iran-related disclosure, tax examinations and disclosed legal or environmental matters.